PTC Therapeutics Q4 Revenue Falls 22.8% to $164.68M, EPS Misses
PTC Therapeutics posted Q4 revenue of $164.68 million, down 22.8% year-over-year and 45.96% below estimates, and reported EPS of -$1.67 versus -$0.24 last year, missing forecasts by 700.58%. Net product sales rose 18.9% to $183.99 million while Translarna and Emflaza revenues dropped 58.4% and 46.3%.
1. Q4 Financial Results
PTC Therapeutics reported Q4 revenue of $164.68 million, a 22.8% year-over-year decline and 45.96% below consensus estimates, and posted EPS of -$1.67 compared to -$0.24 a year ago, missing forecasts by 700.58%.
2. Segment Performance Breakdown
Net product sales grew 18.9% to $183.99 million and royalty revenue increased 36.5% to $79.39 million, while Translarna sales fell 58.4% to $39 million and Emflaza revenue dropped 46.3% to $27.1 million; collaboration income declined to -$0.07 million.
3. Market Response and Outlook
Shares have underperformed broader benchmarks with an 8.8% decline over the past month as investors weigh the steep revenue and earnings misses; the stock carries a Hold rating pending further visibility on collaboration and product growth drivers.